Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04393285 · ClinicalTrials.gov registry record · Phase 2

Abemaciclib and Letrozole to Treat Endometrial Cancer

A Phase 2 study of Endometrial Cancer, sponsored by Gynecologic Oncology Group.

Active
Registry status
Phase 2
Development phase
53
Enrollment target
20
Study locations

NCT04393285 is a Phase 2 study of Endometrial Cancer that is active but no longer recruiting, run by Gynecologic Oncology Group. The registered enrollment target is 53 participants, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The trial reports 20 study locations across 10 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04393285, a Phase 2 study of Endometrial Cancer, is active but no longer recruiting, sponsored by Gynecologic Oncology Group.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
53 participants
Enrollment target
20
Study locations

Study Summary

This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either unacceptable toxicity, progression of disease, or investigator/patient request for withdrawal.

Conditions Studied

Endometrial Cancer

Interventions

  • DRUG Letrozole
  • DRUG Abemaciclib

Study Locations (20)

Florida

  • Sylvester Comprehensive Cancer Center-Lennar Foundation Medical Center - Coral Gables
  • Sylevester Comprehensive Cancer Center-Deerfield Beach - Deerfield Beach
  • UF Health Cancer Center - Gainesville
  • University of Miami - Sylvester Cancer Center - Miami
  • UT Health Tower - Miami
  • Advent Health - Orlando - Orlando
  • Sylvester Comprehensive Cancer Center-Plantation - Plantation
  • Cleveland Clinic Florida - Weston

Connecticut

  • Smillow Cancer Care at Greenwich - Greenwich
  • Yale University - New Haven

Massachusetts

  • Tufts Medical Center - Boston
  • University of Massachusetts - Worcester

New Jersey

  • Rutgers Cancer Institute of New Jersey - New Brunswick
  • Holy Name Medical Center - Teaneck

Alabama

  • University of South Alabama Mitchell Cancer Center - Mobile

Alaska

  • Alaska Women's Cancer Care - Anchorage

Georgia

  • Lewis Cancer & Research Pavilion - Savannah

Illinois

  • University of Chicago - Chicago

Trial Details

FieldValue
Enrollment Target 53 participants
Start Date 2020-10-10
Est. Completion 2026-12-31
Phase Phase 2

Sponsor

Gynecologic Oncology Group

154 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04393285

The ClinicalTrials.gov registry entry for NCT04393285 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 53 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 524-participant average among 181 other Endometrial Cancer trials with a reported enrollment target (90% lower). The listed sponsor is Gynecologic Oncology Group, which has 154 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Endometrial Cancer appearing as the primary indexed condition, and to 2 interventions - of which Letrozole is the first listed.

NCT04393285 reports 20 study locations spanning 10 distinct geographic areas - top geographies include Florida, Connecticut, Massachusetts.

Frequently Asked Questions

What is clinical trial NCT04393285 about?

NCT04393285 is a clinical study titled "Abemaciclib and Letrozole to Treat Endometrial Cancer". This is a phase II single arm trial to determine the percentage of patients without evidence of disease progression on abemaciclib and letrozole in advanced stage, persistent or recurrent endometrioid endometrial cancer at 6 months. Treatment will continue until either unacceptable toxicity, progres...

What is the current status of trial NCT04393285?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 53 participants. The study started on 2020-10-10. Estimated completion is 2026-12-31.

What conditions does trial NCT04393285 study?

This clinical trial studies the following conditions: Endometrial Cancer.

What interventions are being tested in trial NCT04393285?

The interventions under investigation include: Letrozole (DRUG), Abemaciclib (DRUG).

Who is sponsoring clinical trial NCT04393285?

This trial is sponsored by Gynecologic Oncology Group, which has 154 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04393285 being conducted?

This trial has 20 study locations across Alabama, Alaska, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Endometrial Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Endometrial Cancer

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.